StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)

Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –

Amneal Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Amneal Pharmaceuticals's enterprise value was $9.55B on Nov 11, 2026, against $6.38B a year earlier. Over the last 5 years it ranged from $2.64B to $9.55B, with a median of $3.80B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$9.55B+49.1%
2025Dec 31, 2025$6.41B+38.1%
2024Dec 31, 2024$4.64B+42.9%
2023Dec 29, 2023$3.25B+18.2%
2022Dec 30, 2022$2.75B-13.3%
2021Dec 31, 2021$3.17B-1.6%
2020Dec 31, 2020$3.22B+0.0%
2019Dec 31, 2019$3.22B-17.6%
2018Dec 31, 2018$3.91B–

More Amneal Pharmaceuticals figures

See a number that looks wrong?